Who are IL2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): IL-2 (interleukin 2), Basiliximab, Tacrolimus, MMF, Prednisolon, anti-CD25 rhMAb, vemurafenib + HD IL-2, Basiliximab, Tacrolimus, MMF, Zenapax®, CellCept® and prednisolone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/il2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

IL2 — Competitive Intelligence Brief

IL2 (IL2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytokine immunotherapy. Area: Oncology.

phase 3 Cytokine immunotherapy IL-2 receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

IL2 (IL2) — Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS. IL-2 (interleukin-2) is a cytokine that activates and expands T cells and natural killer cells to enhance anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IL2 TARGET	IL2	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	phase 3	Cytokine immunotherapy	IL-2 receptor
IL-2 (interleukin 2)	IL-2 (interleukin 2)	King's College London	marketed	Cytokine	IL-2 receptor (IL-2R)
Basiliximab, Tacrolimus, MMF, Prednisolon	Basiliximab, Tacrolimus, MMF, Prednisolon	University Hospital Freiburg	marketed	Immunosuppressive combination regimen	IL-2 receptor (basiliximab), calcineurin (tacrolimus), IMPDH (MMF), glucocorticoid receptor (prednisolone)
anti-CD25 rhMAb	anti-CD25 rhMAb	Peking University People's Hospital	marketed	CD25 antagonist monoclonal antibody	CD25 (IL-2 receptor alpha chain)
vemurafenib + HD IL-2	vemurafenib + HD IL-2	Clinigen, Inc.	marketed	BRAF inhibitor + cytokine immunotherapy	BRAF V600E kinase; IL-2 receptor
Basiliximab, Tacrolimus, MMF	Basiliximab, Tacrolimus, MMF	University Hospital Freiburg	marketed	Immunosuppressive combination therapy	IL-2 receptor (basiliximab); calcineurin (tacrolimus); IMPDH (MMF)
Zenapax®, CellCept® and prednisolone	Zenapax®, CellCept® and prednisolone	University of Oslo School of Pharmacy	marketed	Immunosuppressive combination therapy	IL-2 receptor (daclizumab); inosine monophosphate dehydrogenase (mycophenolate mofetil); glucocorticoid receptor (prednisolone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytokine immunotherapy class)

Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IL2 — Competitive Intelligence Brief. https://druglandscape.com/ci/il2. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab